JPH0662424B2 - Constipation improver containing chondroitin sulfate - Google Patents
Constipation improver containing chondroitin sulfateInfo
- Publication number
- JPH0662424B2 JPH0662424B2 JP4322869A JP32286992A JPH0662424B2 JP H0662424 B2 JPH0662424 B2 JP H0662424B2 JP 4322869 A JP4322869 A JP 4322869A JP 32286992 A JP32286992 A JP 32286992A JP H0662424 B2 JPH0662424 B2 JP H0662424B2
- Authority
- JP
- Japan
- Prior art keywords
- chondroitin sulfate
- constipation
- protein
- present
- lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Description
【０００１】[0001]
【産業上の利用分野】本発明は、健康増進・維持剤に関
し、更に詳しくは、コンドロイチン硫酸含有便秘改善剤
に関する。TECHNICAL FIELD The present invention relates to a health promoting / maintaining agent, and more particularly to a chondroitin sulfate-containing constipation improving agent.
【０００２】[0002]
【従来の技術】コンドロイチン硫酸は、軟骨を中心に一
般に動物の結合組織に分布するムコ多糖類の一種であ
り、組織中では、蛋白質と結合し、プロテオグリカンと
して存在している。BACKGROUND OF THE INVENTION Chondroitin sulfate is a kind of mucopolysaccharide which is generally distributed in connective tissues of animals mainly in cartilage, and is present as a proteoglycan in the tissues by binding to proteins.
【０００３】コンドロイチン硫酸は、通常、ナトリウム
塩として用いられ、薬理学的には、脂血清澄作用、抗凝
固作用、細胞賦活作用、解毒作用、鎮痛作用などを有す
ることが知られている。しかしながら、便秘改善剤とし
ては、未だ適用されていない。Chondroitin sulfate is usually used as a sodium salt, and it is known pharmacologically that it has a fat serum clearing action, an anticoagulant action, a cell activating action, a detoxifying action and an analgesic action. However, it has not yet been applied as a constipation-improving agent.
【０００４】[0004]
【発明が解決しようとする課題】そこで、本発明者ら
は、コンドロイチン硫酸の健康増進・維持剤としての有
効利用について鋭意研究を重ねた結果、コンドロイチン
硫酸又はその塩、レシチン及び蛋白質を一定の割合に配
合した組成物が便秘改善作用を有することによって、便
秘に伴う不快感を解消し、食欲の増進をもたらし、便秘
改善剤として優れた特性を有することを見い出し、本発
明を完成するに至った。Accordingly, the present inventors have conducted extensive studies on effective use of chondroitin sulfate as a health promoting / maintaining agent, and as a result, have found that chondroitin sulfate or a salt thereof, lecithin and protein are contained in a certain proportion. By having a constipation-improving effect on the composition blended in the above, it was found that the discomfort associated with constipation is eliminated, the appetite is enhanced, and the composition has excellent properties as a constipation-improving agent, and the present invention has been completed. .
【０００５】[0005]
【課題を解決するための手段】本発明の便秘改善剤は、 コンドロイチン硫酸又はそのアルカリ金属もしくはアルカリ土類金属塩 １〜４０重量部、 レシチン ０．５〜２０重量部及び 蛋白質 ４０〜９８．５重量部 からなることを特徴とするものである。The constipation-improving agent of the present invention is 1 to 40 parts by weight of chondroitin sulfate or its alkali metal or alkaline earth metal salt, 0.5 to 20 parts by weight of lecithin and 40 to 98.5 parts of protein. It is characterized by comprising parts by weight.
【０００６】本発明において、コンドロイチン硫酸は、
精製したものを用いてもよいし、プロテオグリカンの形
態で用いてもよい。この場合、プロテオグリカン中のコ
ンドロイチン硫酸換算量が前記範囲内であり、プロテオ
グリカン中の蛋白質量と新たに添加する蛋白質の総量が
前記範囲内になるように配合すればよい。In the present invention, chondroitin sulfate is
The purified product may be used, or the proteoglycan may be used. In this case, the amount of chondroitin sulfate in proteoglycan is within the above range, and the amount of protein in proteoglycan and the total amount of newly added protein may be within the above range.
【０００７】コンドロイチン硫酸をプロテオグリカンの
形態で得るには、例えば、サメ、クジラなどの水産動
物、牛、豚などの哺乳動物又は鳥等の軟骨を原料とし、
中性塩法、アルカリ法、酵素法、オートクレーブ法など
の公知の方法に従って抽出し、脂肪・固形分などを除去
した後、乾燥すればよい。また、脂肪・固形分を除去し
た後、更に蛋白分解酵素を用いて除蛋白処理し、アルコ
ール沈殿による公知の方法に従って精製すれば、コンド
ロイチン硫酸又はその塩を精製された状態で得ることが
できる。To obtain chondroitin sulfate in the form of proteoglycan, for example, marine animals such as sharks and whales, mammals such as cows and pigs, or cartilage such as birds are used as raw materials.
Extraction may be performed according to a known method such as a neutral salt method, an alkali method, an enzyme method, an autoclave method, etc. to remove fats and solids, and then drying. In addition, chondroitin sulfate or a salt thereof can be obtained in a purified state by removing fats and solids, further deproteinizing with a proteolytic enzyme, and purifying according to a known method by alcohol precipitation.
【０００８】コンドロイチン硫酸の塩としては、通常、
ナトリウム塩を用いるが、カルシウム塩、カリウム塩な
どを用いてもよい。The salt of chondroitin sulfate is usually
Although sodium salt is used, calcium salt, potassium salt and the like may be used.
【０００９】蛋白質としては、プロテオグリカン由来の
ものの他、通常、卵白由来の蛋白又は全卵白、牛乳蛋
白、ゼラチンなどの動物性蛋白質及び大豆蛋白などの植
物性蛋白質などを用いることができる。As the protein, in addition to those derived from proteoglycan, proteins derived from egg white or animal proteins such as whole egg white, milk protein and gelatin, and vegetable proteins such as soybean protein can be used.
【００１０】コンドロイチン硫酸若しくはその塩又はレ
シチンの配合割合が前記下限未満であると、便秘改善作
用が不充分となる。If the compounding ratio of chondroitin sulfate or its salt or lecithin is less than the lower limit, the constipation-improving effect becomes insufficient.
【００１１】本発明の便秘改善剤には、主成分であるコ
ンドロイチン硫酸又はその塩、レシチン及び蛋白質の他
に、ビタミンＡ、Ｂ1 、Ｂ2 、Ｂ6 、Ｂ12、Ｃ、Ｄ、
Ｅ、パントテン酸、ニコチン酸アミド、ビオチン、葉
酸、イノシトール、タウリン、人参エキスのような植物
エキス、各種アミノ酸、各種ミネラルなどを適宜配合す
ることができるが、その総配合量は、コンドロイチン硫
酸又はその塩、レシチン及び蛋白質の総量１００重量部
に対して１０重量部以下とすることが好ましい。The constipation-improving agent of the present invention comprises vitamins A, B 1 , B 2 , B 6 , B 12 , C, D, in addition to chondroitin sulfate or its salt, lecithin and protein which are the main components.
E, pantothenic acid, nicotinic acid amide, biotin, folic acid, inositol, taurine, plant extracts such as ginseng extract, various amino acids, various minerals and the like can be appropriately mixed, but the total amount thereof is chondroitin sulfate or its It is preferably 10 parts by weight or less based on 100 parts by weight of the total amount of salt, lecithin and protein.
【００１２】本発明の便秘改善剤は、通常、液剤、顆粒
剤、錠剤、トローチ又はカプセル剤として用いる。The constipation-improving agent of the present invention is usually used as a liquid, granule, tablet, troche or capsule.
【００１３】使用に際しては、通常、本発明品を１回に
１〜２g 、１日当り１〜３回服用する。In use, the product of the present invention is usually taken in an amount of 1 to 2 g at a time, 1 to 3 times a day.
【００１４】[0014]
【実施例】以下、実施例及び処方例により本発明を更に
詳細に説明するが、これらは、本発明の範囲を何ら制限
するものではない。The present invention will be described in more detail with reference to Examples and Formulations, but these do not limit the scope of the present invention.
【００１５】実施例 （１）検体の調製 以下に示す本発明品の液剤（検体Ａ及びＢ）を調製し
た。Example (1) Preparation of Specimen The following liquid preparations (specimens A and B) of the present invention were prepared.
【００１６】検体Ａ：コンドロイチン硫酸ナトリウム
（分子量約１０，０００）１５％、レシチン５％及び大
豆蛋白８０％を含む組成物の１０％水溶液 検体Ｂ：軟骨抽出物９５％（コンドロイチン硫酸ナトリ
ウム１３％、蛋白質８２％に相当する）及びレシチン５
％を含む組成物の１０％水溶液 軟骨抽出物は豚気管軟骨を１２１℃に１２０分間保った
後、遠心分離し、脂肪・固形分を除去して得られた抽出
液を噴霧乾燥して得たもので、このものはコンドロイチ
ン硫酸ナトリウム１３．７％、蛋白質８６．３％を含有
していた。Specimen A: 10% aqueous solution of a composition containing 15% sodium chondroitin sulfate (molecular weight about 10,000), 5% lecithin and 80% soybean protein Specimen B: 95% cartilage extract (13% sodium chondroitin sulfate, Equivalent to 82% of protein) and lecithin 5
A 10% aqueous solution of a composition containing 10% cartilage extract was obtained by spray-drying the extract obtained by keeping pig tracheal cartilage at 121 ° C. for 120 minutes, centrifuging it, and removing fat and solids. This product contained 13.7% sodium chondroitin sulfate and 86.3% protein.
【００１７】（２）便秘に対する作用 便秘で苦しんでいる人の中、便通が週１回の人１５人、
同じく週２回の人２３人に前記検体Ａ又は検体Ｂに相当
する組成物をそれぞれ１回当り１．５g を１日に３回、
連日７日間服用させた結果は次の通りであった。(2) Effect on constipation Among those suffering from constipation, 15 who have a bowel movement once a week,
Similarly, to 23 persons twice a week, 1.5 g each of the compositions corresponding to the above-mentioned sample A or sample B was given 3 times a day,
The results of taking the drug for 7 consecutive days were as follows.
【００１８】[0018]
【表１】 [Table 1]
【００１９】以上の結果より明らかな如く、本発明品は
何れも便秘に対して顕著な改善効果を示した。As is clear from the above results, all the products of the present invention showed a remarkable improving effect on constipation.
【００２０】（３）急性毒性 コンドロイチン硫酸ナトリウム１５％、レシチン５％及
び軟骨由来の蛋白質８０％よりなる本発明品の経口投与
による急性毒性値を測定したところ、以下に示す結果を
得た。(3) Acute toxicity The acute toxicity value by oral administration of the product of the present invention comprising 15% sodium chondroitin sulfate, 5% lecithin and 80% protein derived from cartilage was measured, and the following results were obtained.
【００２１】[0021]
【表２】 [Table 2]
【００２２】以上の結果より明らかな如く、本発明品は
極めて低毒性である。As is clear from the above results, the product of the present invention has extremely low toxicity.
【００２３】処方例１ コンドロイチン硫酸ナトリウム ２０g レシチン ３g 乾燥蛋白 ７７g を混和し、常法に従って、顆粒とした。Formulation Example 1 Sodium chondroitin sulfate 20 g Lecithin 3 g Dry protein 77 g were mixed and granulated according to a conventional method.
【００２４】処方例２ 軟骨抽出物 ９５g （コンドロイチン硫酸ナトリウム １３g 蛋白質 ８２g に相当する） レシチン ５g を混和し、常法に従って顆粒とし、カプセルに充填し
た。Formulation Example 2 95 g of cartilage extract (corresponding to 13 g of sodium chondroitin sulfate and 82 g of protein) 5 g of lecithin were mixed and made into granules according to a conventional method and filled into capsules.
【００２５】処方例３ コンドロイチン硫酸ナトリウム ３０g レシチン ３g ゼラチン ６７ｇ パルミチン酸レチノール ９，０００ビタミン
Ａ単位 塩酸チアミン １００ｍｇ ビタミンＢ2 ６０mg ビタミンＢ6 ６０mg ビタミンＣ １，０００mg パントテン酸カルシウム ５０mg ニコチン酸アミド ２００mg 酢酸トコフェロール ５０mg エルゴカルシフェロール ８，０００国際単位 を混和し、常法に従って顆粒とした。Formulation Example 3 Sodium chondroitin sulfate 30 g Lecithin 3 g Gelatin 67 g Retinol palmitate 9,000 Vitamin A unit Thiamine hydrochloride 100 mg Vitamin B 2 60 mg Vitamin B 6 60 mg Vitamin C 1,000 mg Calcium pantothenate 50 mg Nicotinamide 200 mg Tocopherol acetate 50 mg Ergocalciferol 8,000 international units were mixed and made into granules according to a conventional method.
【００２６】処方例４ 処方例２の処方の混和物１００g に 塩酸チアミン ５０mg ビタミンＢ2 ２５mg ビタミンＢ6 ２５mg パントテン酸カルシウム ２５mg ニコチン酸アミド １００mg メチオニン １００mg アスパラギン酸ナトリウム ３００mg 塩酸リジン １００mg カルニチン ２００mg グリセロリン酸カルシウム ３００mg 人参エキス ５０mg を加えて混和し、水を加えて全量を１，０００mlとし
た。Formulation Example 4 Thiamine amine 50 mg Vitamin B 2 25 mg Vitamin B 6 25 mg Calcium pantothenate 25 mg Nicotinic acid amide 100 mg Methionine 100 mg Sodium aspartate 300 mg Lysine hydrochloride 100 mg Carnitine 200 mg Carb glycerophosphate 300 mg in 100 g of the mixture of the formulation of Formulation Example 2 50 mg of the extract was added and mixed, and water was added to bring the total amount to 1,000 ml.
【００２７】[0027]
【発明の効果】本発明の便秘改善剤は、便秘改善、通常
の体力維持、疲労回復、胃部・下腹部の不快感、更年期
障害、わる酔、滋養強壮、虚弱体質などに広く適用され
る。EFFECTS OF THE INVENTION The constipation-improving agent of the present invention is widely applied for improving constipation, maintaining normal physical strength, recovering from fatigue, stomach / lower abdominal discomfort, menopause, sickness, nourishing tonic, weak constitution, etc. .
Claims (1)
属もしくはアルカリ 土類金属塩 １〜４０重量部、 レシチン ０．５〜２０重量部及び 蛋白質 ４０〜９８．５重量部 からなることを特徴とする便秘改善剤。1. A constipation-improving agent comprising 1 to 40 parts by weight of chondroitin sulfate or its alkali metal or alkaline earth metal salt, 0.5 to 20 parts by weight of lecithin, and 40 to 98.5 parts by weight of protein. .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4322869A JPH0662424B2 (en) | 1992-12-02 | 1992-12-02 | Constipation improver containing chondroitin sulfate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4322869A JPH0662424B2 (en) | 1992-12-02 | 1992-12-02 | Constipation improver containing chondroitin sulfate |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59165658A Division JPS6144822A (en) | 1984-08-09 | 1984-08-09 | Health promoting and keeping agent containing chondroitin sulfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH05320057A JPH05320057A (en) | 1993-12-03 |
| JPH0662424B2 true JPH0662424B2 (en) | 1994-08-17 |
Family
ID=18148526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4322869A Expired - Lifetime JPH0662424B2 (en) | 1992-12-02 | 1992-12-02 | Constipation improver containing chondroitin sulfate |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0662424B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL134701A0 (en) | 2000-02-23 | 2001-04-30 | J P M E D Ltd | Homogeneous solid matrix containing vegetable proteins |
-
1992
- 1992-12-02 JP JP4322869A patent/JPH0662424B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH05320057A (en) | 1993-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4975751B2 (en) | Minerals, collagens and chelates and their production and use | |
| US4804745A (en) | Agents for the treatment of arthroses | |
| US6838440B2 (en) | Kolla2-desiccated avian sternal cartilage powder | |
| Gross | Studies on the formation of collagen: IV. Effect of vitamin C deficiency on the neutral salt-extractible collagen of skin | |
| JPH0416165A (en) | Preparation of bone-fortifying food, feed and medicine and bone peptide and protein mixture to be used therein | |
| JPH05176715A (en) | Whey-originating fraction proliferating osteoblasts and strengthening bones and food, feed or medicine for strengthening bones | |
| JP2004097021A (en) | Wakame protein-containing composition, and wakame protein-containing food | |
| JPH0534341B2 (en) | ||
| JPH0662424B2 (en) | Constipation improver containing chondroitin sulfate | |
| EP0073173B1 (en) | Products extracted from invertebrate sea-animals, their preparation and their uses in dietetics,pharmaceutics and cosmetology | |
| MXPA05004994A (en) | Composition for the treatment of gastrointestinal disorders. | |
| JPH0662425B2 (en) | Hyaluronic acid-containing blood lipid lowering agent | |
| JPH0534340B2 (en) | ||
| JPH0662423B2 (en) | Gastric mucosa protective agent containing chondroitin sulfate | |
| JPWO2009057282A1 (en) | Food material for suppressing bone resorption | |
| JP2001314173A (en) | Composition for food | |
| JP7357189B1 (en) | Collagen-containing composition derived from fish cartilage | |
| JP4695629B2 (en) | Indigestible | |
| JP2579593B2 (en) | Health food containing calcium-containing composition excellent in absorbability, drug containing the composition | |
| JPH09132531A (en) | Composition for additive to liquid food and liquid food | |
| JP2002154968A (en) | Composition for preventing or curing arthritis, or for improving symptom of arthritis | |
| EP0138784A2 (en) | Arabinogalactans, their preparation and compositions containing same | |
| JP6629469B1 (en) | An antihypertensive agent comprising a chondroitin sulfate-containing porcine cartilage extract as an active ingredient and a food composition containing the same | |
| JP2004099461A (en) | Porphyra species protein-containing composition and food | |
| JP2021029122A (en) | Composition for inhibiting clostridium cluster in enteric bacterial flora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |